(Q44633281)

4 December 2017

Modafinil in children with attention-deficit hyperactivity disorder (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0887-8994(03)00148-6

25 March 2024

author name string

Thomas A. Rugino

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580657

25 March 2024

Teresa C. Samsock

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14580657

25 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14580657

25 March 2024

publication date

1 August 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0887899403001486?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0887-8994(03)00148-6

https://api.elsevier.com/content/article/PII:S0887899403001486?httpAccept=text/plain

25 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0887-8994(03)00148-6

25 March 2024

1 reference

4 December 2017

29

1 reference

4 December 2017

2

1 reference

4 December 2017

136-142

1 reference

Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Modafinil and cortical gamma-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Modafinil prevents glutamate cytotoxicity in cultured cortical neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Hypothalamic arousal regions are activated during modafinil-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Dopaminergic role in stimulant-induced wakefulness.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Modafinil binds to the dopamine uptake carrier site with low affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Effect of modafinil on pancreatic exocrine secretion in the rat. A comparison with methadone

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Attention deficit disorder and hyperactivity--changes in hypothalamic function in hyperactive children: a new model.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Hypothalamic-pituitary-adrenal axis function in children with attention-deficit hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Methylphenidate and growth in hyperactive children. A controlled withdrawal study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-8994%2803%2900148-6

7 January 2021

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

series ordinal

7

1 reference

https://api.crossref.org/works/10.1016/S0887-8994(03)00148-6

25 March 2024

Identifiers

1 reference

4 December 2017

1 reference